Seth J. Baum, MD In 2013 Dr. Tom Frieden, Director of the CDC, judiciously proclaimed that “even one preventable death is one too many.” Just three years later we are mired in debates concerning cost effectiveness of innovative medicines. We argue about not only the price of drugs, but also the monetized value of a…

Read More

The commoditization of doctors is a pattern both insidious and distressing. Examining reimbursement and medical practitioner nomenclature trends over the past few decades, one can see with certainty that doctors have been branded commodities; we are no longer individuals possessing unique qualities and skillsets. In the minds of insurers and patients all doctors are created…

Read More

by Seth J. Baum MD Recently, there have been several articles discussing the development, efficacy, cost and long-term impact of novel cholesterol lowering drugs – called PCSK9 inhibitors – new drugs that show the capacity to greatly reduce the levels of LDL, or “bad”, cholesterol in an individual’s bloodstream. Insurance providers have pushed back aggressively…

Read More

by Seth J. Baum, MD A recent article by Caroline Humer and Ransdell Pierson for Reuters reported on the unexpectedly paltry number of prescriptions for PCSK9 inhibitors, the revolutionary cholesterol lowering drugs that were FDA approved in the summer of 2015. Insurance providers had viewed these costly medications as a potentially grave threat to their…

Read More

by Seth J. Baum, MD Sporadically during the presidential debates we hear discussions that attempt to resolve issues. One of the most contentious one relates to healthcare, Obamacare specifically. Few would argue that we are better off today than we were prior to the institution of the Affordable Care Act. Those in favor point to…

Read More